Monthly Archives: December 2015

In local economic news:

Louisiana lost 11,500 jobs over the 12 months ending November 30th, with only the Baton Rouge and Lake Charles metro areas gaining jobs, according to non seasonally adjusted figures released by the Louisiana Workforce Commission.

In national news:

Mother Jones published a profile of labor super-lawyer Shannon “Sledgehammer” Liss-Riordan, the attorney behind the massive San Francisco misclassification lawsuit against Uber.

Diabetes and Comp: One Part of a National Public Health Crisis

This year, a study published in the Journal of the American Medical Association (JAMA) made a splash when its authors declared that a full half of the American population had either diabetes or pre-diabetes (i.e. borderline blood sugar) between 2008 and 2012. The vast majority of these cases are type 2 diabetes, which is often due to lifestyle factors, as opposed to type 1, which is genetic. While those numbers may seem bleak, diagnosis rates remained relatively steady throughout that period, so the researchers surmise that prevention efforts, including private workplace wellness programs, are making some impact. However, the formerly uncommon “adult onset” condition is now being diagnosed in children as young as three years old. Where does workers’ comp fit into this grim picture? We asked local experts to find out.

In national news:

The latest piece in ProPublica’s “Insult to Injury” series on workers’ comp issues frames a discussion about “cost containment” firms and their influence in state comp systems with a critique of the lavish entertainment at the annual National Workers’ Compensation and Disability Conference and Expo in Las Vegas.

In industry news:

Insurance Journal compiled its most read P/C lists and rankings articles for 2015, and four of the top 20 are about the workers’ comp industry.

In medical news:

The FDA published a response to an article published in MedPage Today claiming that the agency did not require the sponsor of Narcan nasal spray, which contains naloxone as its active ingredient, to conduct clinical studies in a “real world” setting before approving the product.

In national news:

Purdue Pharma, the maker of OxyContin, will pay the state of Kentucky $24 million over the next eight years as part of the settlement of a long-running lawsuit that accused the company of misleading the public.

In regulatory news:

The DEA recently eased some of the regulatory requirements imposed by the Controlled Substances Act (CSA) for those who are conducting FDA-approved clinical trials on cannabidiol.